Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 22 entries
Sorted by: Best Match Show Resources per page
The relation between psychological distress and medication adherence in lung transplant candidates and recipients: A cross-sectional study.

Journal of clinical nursing

Wessels-Bakker MJ, van de Graaf EA, Kwakkel-van Erp JM, Heijerman HG, Cahn W, Schappin R.
PMID: 34216066
J Clin Nurs. 2021 Jul 02; doi: 10.1111/jocn.15931. Epub 2021 Jul 02.

AIMS AND OBJECTIVES: To explore the prevalence of psychological distress such as anxiety, depression and post-traumatic stress disorder and its associations with medication adherence in lung transplant patients.BACKGROUND: Psychological distress after lung transplantation may impact clinical outcomes by associated...

Cite
Wessels-Bakker MJ, van de Graaf EA, Kwakkel-van Erp JM, et al. The relation between psychological distress and medication adherence in lung transplant candidates and recipients: A cross-sectional study. J Clin Nurs. 2021;doi: 10.1111/jocn.15931.
Wessels-Bakker, M. J., van de Graaf, E. A., Kwakkel-van Erp, J. M., Heijerman, H. G., Cahn, W., & Schappin, R. (2021). The relation between psychological distress and medication adherence in lung transplant candidates and recipients: A cross-sectional study. Journal of clinical nursing, . https://doi.org/10.1111/jocn.15931
Wessels-Bakker, Marion J, et al. "The relation between psychological distress and medication adherence in lung transplant candidates and recipients: A cross-sectional study." Journal of clinical nursing vol. (2021). doi: https://doi.org/10.1111/jocn.15931
Wessels-Bakker MJ, van de Graaf EA, Kwakkel-van Erp JM, Heijerman HG, Cahn W, Schappin R. The relation between psychological distress and medication adherence in lung transplant candidates and recipients: A cross-sectional study. J Clin Nurs. 2021 Jul 02; doi: 10.1111/jocn.15931. Epub 2021 Jul 02. PMID: 34216066.
Copy Download .nbib Format: NLM
The effect of maintenance azithromycin on radiological features in patients with bronchiectasis - Analysis from the BAT randomized controlled trial.

Respiratory medicine

Terpstra LC, Altenburg J, Mohamed Hoesein FA, Bronsveld I, Go S, van Rijn PAC, De Jong PA, Heijerman HGM, Boersma WG.
PMID: 34974413
Respir Med. 2021 Dec 28;192:106718. doi: 10.1016/j.rmed.2021.106718. Epub 2021 Dec 28.

RATIONALE: Bronchiectasis (abnormal dilatation of bronchi) is usually diagnosed by high resolution computed tomography (HRCT) and radiological severity has been found to correspond with clinical outcome. A beneficial effect of macrolides maintenance treatment in frequent exacerbating bronchiectasis patients has...

Cite
Terpstra LC, Altenburg J, Mohamed Hoesein FA, et al. The effect of maintenance azithromycin on radiological features in patients with bronchiectasis - Analysis from the BAT randomized controlled trial. Respir Med. 2021;192:106718doi: 10.1016/j.rmed.2021.106718.
Terpstra, L. C., Altenburg, J., Mohamed Hoesein, F. A., Bronsveld, I., Go, S., van Rijn, P. A. C., De Jong, P. A., Heijerman, H. G. M., & Boersma, W. G. (2021). The effect of maintenance azithromycin on radiological features in patients with bronchiectasis - Analysis from the BAT randomized controlled trial. Respiratory medicine, 192106718. https://doi.org/10.1016/j.rmed.2021.106718
Terpstra, Lotte C, et al. "The effect of maintenance azithromycin on radiological features in patients with bronchiectasis - Analysis from the BAT randomized controlled trial." Respiratory medicine vol. 192 (2021): 106718. doi: https://doi.org/10.1016/j.rmed.2021.106718
Terpstra LC, Altenburg J, Mohamed Hoesein FA, Bronsveld I, Go S, van Rijn PAC, De Jong PA, Heijerman HGM, Boersma WG. The effect of maintenance azithromycin on radiological features in patients with bronchiectasis - Analysis from the BAT randomized controlled trial. Respir Med. 2021 Dec 28;192:106718. doi: 10.1016/j.rmed.2021.106718. Epub 2021 Dec 28. PMID: 34974413.
Copy Download .nbib Format: NLM
Physiological predictors of cardiorespiratory fitness in children and adolescents with cystic fibrosis without ventilatory limitation.

Therapeutic advances in respiratory disease

Burghard M, Takken T, Nap-van der Vlist MM, Nijhof SL, van der Ent CK, Heijerman HGM, Hulzebos HJE.
PMID: 35012387
Ther Adv Respir Dis. 2022 Jan-Dec;16:17534666211070143. doi: 10.1177/17534666211070143.

OBJECTIVES: [1] To investigate the cardiorespiratory fitness (CRF) levels in children and adolescents with cystic fibrosis (CF) with no ventilatory limitation (ventilatory reserve ⩾ 15%) during exercise, and [2] to assess which physiological factors are related to CRF.METHODS: A...

Cite
Burghard M, Takken T, Nap-van der Vlist MM, et al. Physiological predictors of cardiorespiratory fitness in children and adolescents with cystic fibrosis without ventilatory limitation. Ther Adv Respir Dis. 2022;16:17534666211070143doi: 10.1177/17534666211070143.
Burghard, M., Takken, T., Nap-van der Vlist, M. M., Nijhof, S. L., van der Ent, C. K., Heijerman, H. G. M., & Hulzebos, H. J. E. (2022). Physiological predictors of cardiorespiratory fitness in children and adolescents with cystic fibrosis without ventilatory limitation. Therapeutic advances in respiratory disease, 1617534666211070143. https://doi.org/10.1177/17534666211070143
Burghard, Marcella, et al. "Physiological predictors of cardiorespiratory fitness in children and adolescents with cystic fibrosis without ventilatory limitation." Therapeutic advances in respiratory disease vol. 16 (2022): 17534666211070143. doi: https://doi.org/10.1177/17534666211070143
Burghard M, Takken T, Nap-van der Vlist MM, Nijhof SL, van der Ent CK, Heijerman HGM, Hulzebos HJE. Physiological predictors of cardiorespiratory fitness in children and adolescents with cystic fibrosis without ventilatory limitation. Ther Adv Respir Dis. 2022 Jan-Dec;16:17534666211070143. doi: 10.1177/17534666211070143. PMID: 35012387.
Copy Download .nbib Format: NLM
Standards of care for patients with cystic fibrosis: a European consensus.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

Kerem E, Conway S, Elborn S, Heijerman H.
PMID: 15752677
J Cyst Fibros. 2005 Mar;4(1):7-26. doi: 10.1016/j.jcf.2004.12.002.

No abstract available.

Cite
Kerem E, Conway S, Elborn S, et al. Standards of care for patients with cystic fibrosis: a European consensus. J Cyst Fibros. 2005;4(1):7-26doi: 10.1016/j.jcf.2004.12.002.
Kerem, E., Conway, S., Elborn, S., Heijerman, H. (2005). Standards of care for patients with cystic fibrosis: a European consensus. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 4(1), 7-26. https://doi.org/10.1016/j.jcf.2004.12.002
Kerem, Eitan, et al. "Standards of care for patients with cystic fibrosis: a European consensus." Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society vol. 4,1 (2005): 7-26. doi: https://doi.org/10.1016/j.jcf.2004.12.002
Kerem E, Conway S, Elborn S, Heijerman H. Standards of care for patients with cystic fibrosis: a European consensus. J Cyst Fibros. 2005 Mar;4(1):7-26. doi: 10.1016/j.jcf.2004.12.002. PMID: 15752677.
Copy Download .nbib Format: NLM
The Journal of Cystic Fibrosis: a success story.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

Heijerman HG.
PMID: 16439333
J Cyst Fibros. 2006 Jan;5(1):1. doi: 10.1016/j.jcf.2006.01.001.

No abstract available.

Cite
Heijerman HG. The Journal of Cystic Fibrosis: a success story. J Cyst Fibros. 2006;5(1):1doi: 10.1016/j.jcf.2006.01.001.
Heijerman, H. G. (2006). The Journal of Cystic Fibrosis: a success story. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 5(1), 1. https://doi.org/10.1016/j.jcf.2006.01.001
Heijerman, Harry G M. "The Journal of Cystic Fibrosis: a success story." Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society vol. 5,1 (2006): 1. doi: https://doi.org/10.1016/j.jcf.2006.01.001
Heijerman HG. The Journal of Cystic Fibrosis: a success story. J Cyst Fibros. 2006 Jan;5(1):1. doi: 10.1016/j.jcf.2006.01.001. PMID: 16439333.
Copy Download .nbib Format: NLM
Colistin methanesulfonate infusion solutions are stable over time and suitable for home administration.

European journal of hospital pharmacy : science and practice

Post TE, Kamerling IMC, van Rossen RCJM, Burggraaf J, Stevens J, Dijkmans AC, Heijerman HGM, Touw DJ, van Velzen AJ, Wilms EB.
PMID: 31157054
Eur J Hosp Pharm. 2018 Nov;25(6):337-339. doi: 10.1136/ejhpharm-2016-001128. Epub 2017 Mar 18.

The stability of colistin methanesulfonate (CMS) was determined in quadruplicate in elastomeric home infusion pumps containing 1, 2 or 3 MU CMS and in infusion bags with 2 MU CMS all in 100 mL normal saline. Infusions were stored...

Cite
Post TE, Kamerling IMC, van Rossen RCJM, et al. Colistin methanesulfonate infusion solutions are stable over time and suitable for home administration. Eur J Hosp Pharm. 2017;25(6):337-339doi: 10.1136/ejhpharm-2016-001128.
Post, T. E., Kamerling, I. M. C., van Rossen, R. C. J. M., Burggraaf, J., Stevens, J., Dijkmans, A. C., Heijerman, H. G. M., Touw, D. J., van Velzen, A. J., & Wilms, E. B. (2018). Colistin methanesulfonate infusion solutions are stable over time and suitable for home administration. European journal of hospital pharmacy : science and practice, 25(6), 337-339. https://doi.org/10.1136/ejhpharm-2016-001128
Post, Titiaan E, et al. "Colistin methanesulfonate infusion solutions are stable over time and suitable for home administration." European journal of hospital pharmacy : science and practice vol. 25,6 (2018): 337-339. doi: https://doi.org/10.1136/ejhpharm-2016-001128
Post TE, Kamerling IMC, van Rossen RCJM, Burggraaf J, Stevens J, Dijkmans AC, Heijerman HGM, Touw DJ, van Velzen AJ, Wilms EB. Colistin methanesulfonate infusion solutions are stable over time and suitable for home administration. Eur J Hosp Pharm. 2018 Nov;25(6):337-339. doi: 10.1136/ejhpharm-2016-001128. Epub 2017 Mar 18. PMID: 31157054; PMCID: PMC6319398.
Copy Download .nbib Format: NLM
Physiological predictors of cardiorespiratory fitness in children and adolescents with cystic fibrosis without ventilatory limitation.

Therapeutic advances in respiratory disease

Burghard M, Takken T, Nap-van der Vlist MM, Nijhof SL, van der Ent CK, Heijerman HGM, Hulzebos HJE.
PMID: 35012387
Ther Adv Respir Dis. 2022 Jan-Dec;16:17534666211070143. doi: 10.1177/17534666211070143.

OBJECTIVES: [1] To investigate the cardiorespiratory fitness (CRF) levels in children and adolescents with cystic fibrosis (CF) with no ventilatory limitation (ventilatory reserve ⩾ 15%) during exercise, and [2] to assess which physiological factors are related to CRF.METHODS: A...

Cite
Burghard M, Takken T, Nap-van der Vlist MM, et al. Physiological predictors of cardiorespiratory fitness in children and adolescents with cystic fibrosis without ventilatory limitation. Ther Adv Respir Dis. 2022;16:17534666211070143doi: 10.1177/17534666211070143.
Burghard, M., Takken, T., Nap-van der Vlist, M. M., Nijhof, S. L., van der Ent, C. K., Heijerman, H. G. M., & Hulzebos, H. J. E. (2022). Physiological predictors of cardiorespiratory fitness in children and adolescents with cystic fibrosis without ventilatory limitation. Therapeutic advances in respiratory disease, 1617534666211070143. https://doi.org/10.1177/17534666211070143
Burghard, Marcella, et al. "Physiological predictors of cardiorespiratory fitness in children and adolescents with cystic fibrosis without ventilatory limitation." Therapeutic advances in respiratory disease vol. 16 (2022): 17534666211070143. doi: https://doi.org/10.1177/17534666211070143
Burghard M, Takken T, Nap-van der Vlist MM, Nijhof SL, van der Ent CK, Heijerman HGM, Hulzebos HJE. Physiological predictors of cardiorespiratory fitness in children and adolescents with cystic fibrosis without ventilatory limitation. Ther Adv Respir Dis. 2022 Jan-Dec;16:17534666211070143. doi: 10.1177/17534666211070143. PMID: 35012387; PMCID: PMC8755930.
Copy Download .nbib Format: NLM
Physiological predictors of cardiorespiratory fitness in children and adolescents with cystic fibrosis without ventilatory limitation.

Therapeutic advances in respiratory disease

Burghard M, Takken T, Nap-van der Vlist MM, Nijhof SL, van der Ent CK, Heijerman HGM, Hulzebos HJE.
PMID: 35012387
Ther Adv Respir Dis. 2022 Jan-Dec;16:17534666211070143. doi: 10.1177/17534666211070143.

OBJECTIVES: [1] To investigate the cardiorespiratory fitness (CRF) levels in children and adolescents with cystic fibrosis (CF) with no ventilatory limitation (ventilatory reserve ⩾ 15%) during exercise, and [2] to assess which physiological factors are related to CRF.METHODS: A...

Cite
Burghard M, Takken T, Nap-van der Vlist MM, et al. Physiological predictors of cardiorespiratory fitness in children and adolescents with cystic fibrosis without ventilatory limitation. Ther Adv Respir Dis. 2022;16:17534666211070143doi: 10.1177/17534666211070143.
Burghard, M., Takken, T., Nap-van der Vlist, M. M., Nijhof, S. L., van der Ent, C. K., Heijerman, H. G. M., & Hulzebos, H. J. E. (2022). Physiological predictors of cardiorespiratory fitness in children and adolescents with cystic fibrosis without ventilatory limitation. Therapeutic advances in respiratory disease, 1617534666211070143. https://doi.org/10.1177/17534666211070143
Burghard, Marcella, et al. "Physiological predictors of cardiorespiratory fitness in children and adolescents with cystic fibrosis without ventilatory limitation." Therapeutic advances in respiratory disease vol. 16 (2022): 17534666211070143. doi: https://doi.org/10.1177/17534666211070143
Burghard M, Takken T, Nap-van der Vlist MM, Nijhof SL, van der Ent CK, Heijerman HGM, Hulzebos HJE. Physiological predictors of cardiorespiratory fitness in children and adolescents with cystic fibrosis without ventilatory limitation. Ther Adv Respir Dis. 2022 Jan-Dec;16:17534666211070143. doi: 10.1177/17534666211070143. PMID: 35012387.
Copy Download .nbib Format: NLM
Prediction of Real-World Long-Term Outcomes of People with CF Homozygous for the F508del Mutation Treated with CFTR Modulators.

Journal of personalized medicine

Muilwijk D, Bierlaagh M, van Mourik P, Kraaijkamp J, van der Meer R, van den Bor R, Heijerman H, Eijkemans R, Beekman J, van der Ent K.
PMID: 34945848
J Pers Med. 2021 Dec 16;11(12). doi: 10.3390/jpm11121376.

The clinical response to cystic fibrosis transmembrane conductance regulator (CFTR) modulators is variable within people with cystic fibrosis (pwCF) homozygous for the F508del mutation. The prediction of clinical effect in individual patients would be useful to target therapy to...

Cite
Muilwijk D, Bierlaagh M, van Mourik P, et al. Prediction of Real-World Long-Term Outcomes of People with CF Homozygous for the F508del Mutation Treated with CFTR Modulators. J Pers Med. 2021;11(12)doi: 10.3390/jpm11121376.
Muilwijk, D., Bierlaagh, M., van Mourik, P., Kraaijkamp, J., van der Meer, R., van den Bor, R., Heijerman, H., Eijkemans, R., Beekman, J., & van der Ent, K. (2021). Prediction of Real-World Long-Term Outcomes of People with CF Homozygous for the F508del Mutation Treated with CFTR Modulators. Journal of personalized medicine, 11(12), . https://doi.org/10.3390/jpm11121376
Muilwijk, Danya, et al. "Prediction of Real-World Long-Term Outcomes of People with CF Homozygous for the F508del Mutation Treated with CFTR Modulators." Journal of personalized medicine vol. 11,12 (2021). doi: https://doi.org/10.3390/jpm11121376
Muilwijk D, Bierlaagh M, van Mourik P, Kraaijkamp J, van der Meer R, van den Bor R, Heijerman H, Eijkemans R, Beekman J, van der Ent K. Prediction of Real-World Long-Term Outcomes of People with CF Homozygous for the F508del Mutation Treated with CFTR Modulators. J Pers Med. 2021 Dec 16;11(12). doi: 10.3390/jpm11121376. PMID: 34945848; PMCID: PMC8707616.
Copy Download .nbib Format: NLM
Individual and Group Response of Treatment with Ivacaftor on Airway and Gut Microbiota in People with CF and a S1251N Mutation.

Journal of personalized medicine

Kristensen MI, de Winter-de Groot KM, Berkers G, Chu MLJN, Arp K, Ghijsen S, Heijerman HGM, Arets HGM, Majoor CJ, Janssens HM, van der Meer R, Bogaert D, van der Ent CK.
PMID: 33925519
J Pers Med. 2021 Apr 27;11(5). doi: 10.3390/jpm11050350.

Ivacaftor has been shown to restore the functionality of the S1251N (also known as c.3752G>A) mutated CFTR, which may cause alterations in both airway and gut physiology and micro-environment, resulting in a change of microbiota in these organs. The...

Cite
Kristensen MI, de Winter-de Groot KM, Berkers G, et al. Individual and Group Response of Treatment with Ivacaftor on Airway and Gut Microbiota in People with CF and a S1251N Mutation. J Pers Med. 2021;11(5)doi: 10.3390/jpm11050350.
Kristensen, M. I., de Winter-de Groot, K. M., Berkers, G., Chu, M. L. J. N., Arp, K., Ghijsen, S., Heijerman, H. G. M., Arets, H. G. M., Majoor, C. J., Janssens, H. M., van der Meer, R., Bogaert, D., & van der Ent, C. K. (2021). Individual and Group Response of Treatment with Ivacaftor on Airway and Gut Microbiota in People with CF and a S1251N Mutation. Journal of personalized medicine, 11(5), . https://doi.org/10.3390/jpm11050350
Kristensen, Maartje I, et al. "Individual and Group Response of Treatment with Ivacaftor on Airway and Gut Microbiota in People with CF and a S1251N Mutation." Journal of personalized medicine vol. 11,5 (2021). doi: https://doi.org/10.3390/jpm11050350
Kristensen MI, de Winter-de Groot KM, Berkers G, Chu MLJN, Arp K, Ghijsen S, Heijerman HGM, Arets HGM, Majoor CJ, Janssens HM, van der Meer R, Bogaert D, van der Ent CK. Individual and Group Response of Treatment with Ivacaftor on Airway and Gut Microbiota in People with CF and a S1251N Mutation. J Pers Med. 2021 Apr 27;11(5). doi: 10.3390/jpm11050350. PMID: 33925519; PMCID: PMC8146888.
Copy Download .nbib Format: NLM
Transparency and diversity in cystic fibrosis research - Authors' reply.

Lancet (London, England)

McCoy KS, Heijerman H, Taylor-Cousar JL, Waltz D, Sosnay PR, Ramsey BW, Rowe S, Welter J.
PMID: 32861305
Lancet. 2020 Aug 29;396(10251):602. doi: 10.1016/S0140-6736(20)30897-7.

No abstract available.

Cite
McCoy KS, Heijerman H, Taylor-Cousar JL, et al. Transparency and diversity in cystic fibrosis research - Authors' reply. Lancet. 2020;396(10251):602doi: 10.1016/S0140-6736(20)30897-7.
McCoy, K. S., Heijerman, H., Taylor-Cousar, J. L., Waltz, D., Sosnay, P. R., Ramsey, B. W., Rowe, S., & Welter, J. (2020). Transparency and diversity in cystic fibrosis research - Authors' reply. Lancet (London, England), 396(10251), 602. https://doi.org/10.1016/S0140-6736(20)30897-7
McCoy, Karen S, et al. "Transparency and diversity in cystic fibrosis research - Authors' reply." Lancet (London, England) vol. 396,10251 (2020): 602. doi: https://doi.org/10.1016/S0140-6736(20)30897-7
McCoy KS, Heijerman H, Taylor-Cousar JL, Waltz D, Sosnay PR, Ramsey BW, Rowe S, Welter J. Transparency and diversity in cystic fibrosis research - Authors' reply. Lancet. 2020 Aug 29;396(10251):602. doi: 10.1016/S0140-6736(20)30897-7. PMID: 32861305.
Copy Download .nbib Format: NLM
Prevention of drug-related complications in cystic fibrosis.

Current opinion in pulmonary medicine

van der Meer R, Touw DJ, Heijerman HGM.
PMID: 31503211
Curr Opin Pulm Med. 2019 Nov;25(6):666-673. doi: 10.1097/MCP.0000000000000625.

PURPOSE OF REVIEW: Due to continuous development of new drugs and better treatment strategies, survival of patients with cystic fibrosis has changed dramatically. Recently, targeted therapy of cystic fibrosis transmembrane conductance regulator (CFTR) modulators have become available. Despite these...

Cite
van der Meer R, Touw DJ, Heijerman HGM. Prevention of drug-related complications in cystic fibrosis. Curr Opin Pulm Med. 2019;25(6):666-673doi: 10.1097/MCP.0000000000000625.
van der Meer, R., Touw, D. J., & Heijerman, H. G. M. (2019). Prevention of drug-related complications in cystic fibrosis. Current opinion in pulmonary medicine, 25(6), 666-673. https://doi.org/10.1097/MCP.0000000000000625
van der Meer, Renske, et al. "Prevention of drug-related complications in cystic fibrosis." Current opinion in pulmonary medicine vol. 25,6 (2019): 666-673. doi: https://doi.org/10.1097/MCP.0000000000000625
van der Meer R, Touw DJ, Heijerman HGM. Prevention of drug-related complications in cystic fibrosis. Curr Opin Pulm Med. 2019 Nov;25(6):666-673. doi: 10.1097/MCP.0000000000000625. PMID: 31503211.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 22 entries